News

ASML Holding NV Shows Resilience Amid Order Declines

ASML Holding NV Shows Resilience Amid Order Declines

Stifel Maintains Hold Rating for ASML Holding NV

Stifel has reaffirmed its Hold rating on ASML Holding NV (NASDAQ: ASML), maintaining a price target of EUR 850.00. Their analysis reflects a significant downturn in Q3 orders, which sharply fell to €2.6 billion from €5.6 billion in Q2. Notably, orders for EUV systems saw a decrease from €2.5 billion to €1.4 billion during this period. Logic orders reduced significantly as well, down to €1.2 billion in Q3 from €4.1 billion previously, while memory orders decreased slightly to €1.4 billion compared to €1.5 billion in Q2.

Q4 Projections Provide a Ray of Hope

Despite the order drop, ASML has issued robust guidance for Q4, forecasting sales between €8.8 billion and €9.2 billion, in line with a consensus estimate of €9.0 billion. They anticipate a gross margin ranging between 49% and 50%, which is just below the consensus expectation of 51.4%. This could indicate a modest shortfall in EBIT levels when taking into account operating expenses.

Analysts Offer Diverging Views on ASML's Outlook

In light of the quarterly results, ASML has been under the microscope from various analysts. For instance, Citi retained a Buy rating on ASML, citing underlying trends like accelerated digital transformation and advancements in EUV technology despite the lower Q3 orders and 2025 guidance. Raymond James has also adjusted its price target downward but continues to uphold a Strong Buy rating, evaluating near-term bookings and 2025 financial projections.

Changes from Other Analysts

Morgan Stanley has shifted its position on ASML, moving from an Overweight to an Equalweight rating, slashing its price target on concerns of a possible spending slowdown that could affect earnings growth over the next couple of years. Alternatively, while Deutsche Bank has lowered its price target due to expectations of a 22% decrease in sales to China by 2025, it has maintained its Buy rating. BofA Securities has also adjusted its price target, reflecting lower earnings projections while sustaining a Buy recommendation. In a contrasting move, UBS has downgraded ASML from Buy to Neutral, while Barclays upgraded it from Equal Weight to Overweight.

InvestingPro Insights on ASML

Insights from InvestingPro regarding ASML's recent financial performance and market dynamics paint a broader picture beyond Stifel's analysis. The firm boasts a market capitalization of $286.33 billion, indicating a solid marketplace presence. ASML's P/E ratio stands at 40.29, revealing a willingness among investors to pay a premium for these stocks, indicative of confidence in the company's long-term viability.

Financial Health and Market Positioning

Furthermore, ASML is noted as a key player in the Semiconductors & Semiconductor Equipment sector, highlighting its critical role in EUV system manufacturing. The company has upheld dividend payments consistently for 18 years, showcasing financial stability amidst industry cyclicality. The most recent revenue report posted revenue of $27.26 billion over the last twelve months, complemented by a robust gross profit margin of 51.44%, aligning closely with the anticipated Q4 guidance.

Frequently Asked Questions

What is the current rating on ASML from Stifel?

Stifel maintains a Hold rating on ASML Holding NV with a price target of EUR 850.00.

How did ASML's Q3 orders compare to Q2?

ASML's Q3 orders declined significantly to €2.6 billion from €5.6 billion in Q2.

What are the projections for ASML's Q4 sales?

ASML projects Q4 sales in the range of €8.8 billion to €9.2 billion.

Which analyst maintained a Buy rating despite recent challenges?

Citi has kept a Buy rating on ASML, focusing on trends like digital transformation.

What is ASML’s market position and performance?

ASML has a market capitalization of $286.33 billion and a strong P/E ratio, indicating confidence in its long-term success.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 33

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 37

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 29

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 40

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 44

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from APA Corporation's Q3 2024 Financial Update

Updated Category News Views 291

Insights from APA Corporation's Q3 2024 Financial Update HOUSTON -- APA Corporation (Nasdaq: APA) has released key information regarding its third-quarter 2024 financial and operational results. This supplemental information serves as a guide for investors, analysts, and stakeholders to help them form their own estimates regarding the company's performance. Understanding...

Continue Reading
Exploring the Growing Trends in the US Coffee Market to 2034

Updated Category News Views 394

Insights on the US Coffee Market Growth The US coffee market is currently gearing up for an exciting decade ahead, with projections indicating it could reach USD 150.88 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% from 2025. This surge is largely influenced by shifting consumer preferences towards premium and specialty coffee, along with an...

Continue Reading
Insights into Great Lakes Dredge & Dock's Upcoming Earnings

Updated Category News Views 125

Understanding the Upcoming Earnings Announcement Great Lakes Dredge & Dock (NASDAQ: GLDD) is gearing up for its quarterly earnings report, and investors are eager to glean insights from the announcement. The anticipation is palpable as analysts forecast an earnings per share (EPS) of $0.09, signalling potential growth for the company. Market Reactions and Guidance It's...

Continue Reading
Calmére Estate Winery Sold, Signaling Growth in Napa Valley

Updated Category News Views 306

Calmére Estate Winery Changes Hands in Major Sale Napa Valley has long been a beacon for wine enthusiasts and savvy investors alike. The recent transaction involving Calmére Estate Winery showcases the continued potential of this iconic region. The winery, known for its exquisite Chardonnay and Pinot Noir, has been a part of the Carneros American Viticultural Area (AVA)...

Continue Reading
Mr. Splash Car Wash Partners with NBA Stars for Growth

Updated Category News Views 204

Mr. Splash Car Wash Takes a Strategic Step Forward Mr. Splash Car Wash, a notable name in the express car wash industry, has recently entered into a strategic partnership with NBA stars Giannis and Thanasis Antetokounmpo, along with Michael Carter-Williams. This collaboration aims to elevate the brand's presence in the Midwest, showcasing Mr. Splash's commitment to...

Continue Reading